Original Articles Open access

Efficacy of intranasal fluticasone propionate nano nasal spray in management of chronic rhinitis: a randomized clinical trial

Authors

Published
30 December 2022
Section
Original Articles
DOI
10.4081/itjm.2022.1545

Abstract

Common inflammatory conditions of the airways, such as chronic rhinitis, nasal polyposis, seasonal and chronic allergic rhinitis can greatly affect a patient’s health and quality of life. For each of these disorders, intranasal corticosteroids are suggested as a component of the therapy regimen because they can assist to lessen symptoms by reducing inflammation. In this randomized controlled trial, 30 people with rhinitis were enrolled to evaluate a new nano formulation of fluticasone propionate nano-nasal spray (FP-NNS) with commercially available nasal spray called FP-NS for the treatment of allergic rhinitis (15 to 60 years). 50 mcg dosages of FP-NNS were administered to patients in the morning and evening. This regimen was administered as a nasal spray for a 4-week effectiveness and safety phase. Analysis of variance was used to evaluate each efficacy endpoint. More of our clinical studies have shown that FP-NNS reduces inflammatory indicators in adults and children.

Keywords

References

  1. Poluan FH, Marlina L. Prevalence and risk factor of chronic rhinosinusitis and the impact on quality of life in students of the Medical Faculty Christian University of Indonesia in 2018. J Drug Delivery Ther 2021;11:154-62.
  2. Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cystic Fibrosis 2009;8:S10-4.
  3. Bunzen DL, Campos A, Leão FS, et al. Efficacy of functional endoscopic sinus surgery for symptoms in chronic rhinosinusitis with or without polyposis. Brazil J Otorhinolaryngol 2006;72:242-6.
  4. Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol 2015;11:349-61.
  5. Howard BE, Lal D. Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis. Curr Allergy Asthma Rep 2013;13:236-43.
  6. Drazdauskaitė G, Layhadi JA, Shamji MH. Mechanisms of allergen immunotherapy in allergic rhinitis. Curr Allergy Asthma Rep 2021;21:1-17.
  7. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin 2010;26:2047-55.
  8. González-Núñez V, Valero AL, Mullol J. Impact of sleep as a specific marker of quality of life in allergic rhinitis. Curr Allergy Asthma Rep 2013;13:131-41.
  9. Scadding GK. Optimal management of allergic rhinitis. Archiv Dis Childhood 2015;100:576-82.
  10. Carr WW, Ratner P, Munzel U, et al. In comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc 2012.
  11. Komi DEA, Mortaz E, Amani S, et al. The role of mast cells in IgE-independent lung diseases. Clin Rev Allergy Immunol 2020;58:377-87.
  12. Parikh A, Scadding G, Darby Y, Baker R. Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology 2001;39:75-9.
  13. Adriaensen GF, Lim KH, Fokkens WJ. In Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. Int Forum Allergy Rhinol 2017:813-20.
  14. Umerska A, Mouzouvi CR, Bigot A, Saulnier P. Formulation and nebulization of fluticasone propionate-loaded lipid nanocarriers. Int J Pharm 2015;493:224-32.
  15. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. Int Scholarly Res Notices 2012;2012.
  16. Far J, Abdel-Haq M, Gruber M, Abu Ammar A. Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. ACS Omega 2020;5:7432-9.
  17. Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig 2015;5:124.
  18. Formica ML, Real DA, Picchio ML, et al. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today 2022;29:101631;
  19. Li X, Xue M, Raabe OG, et al. Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based therapeutics. Nanomed Nanotechnol Biol Med 2015;11:1377-85.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2022 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.